IGF-1 LR3 is the most direct anabolic peptide in the strength stack. While GH secretagogues nudge your pituitary to release growth hormone — which then signals the liver to produce IGF-1 — IGF-1 LR3 is the IGF-1 itself, injected directly. The result is faster, more pronounced anabolic signaling than secretagogues can produce, with a correspondingly sharper risk profile.
This guide covers what IGF-1 LR3 actually is, how it differs from natural IGF-1 and from GH peptides, the dosing patterns reported in the strength community, and the real safety considerations that make this peptide the most-cautioned in the category.
What IGF-1 LR3 actually is
IGF-1 LR3 stands for Long-Arg3 Insulin-like Growth Factor-1. It's a synthetic analogue of natural IGF-1 (which is 70 amino acids) with two specific modifications:
- Arginine substituted for glutamic acid at position 3 (the "Arg3" part)
- 13-amino-acid N-terminal extension (the "Long" part)
Both modifications change how IGF-1 LR3 behaves in the body:
- Reduced IGFBP binding — natural IGF-1 is rapidly bound by IGF binding proteins (IGFBPs), which sequester most circulating IGF-1. IGF-1 LR3 binds IGFBPs much less, so a higher fraction stays free and bioactive.
- Extended half-life — natural IGF-1 has a half-life of 10–15 minutes. IGF-1 LR3 has a half-life of 20–30 hours.
- Higher per-mg potency — at the IGF-1 receptor, IGF-1 LR3 is roughly 2–3x more potent than natural IGF-1.
The combined result: a single IGF-1 LR3 injection produces sustained, strong IGF-1-receptor activation lasting most of a day. Natural IGF-1 would need continuous infusion to match.
How IGF-1 LR3 differs from GH secretagogues
This is the most-asked comparison, and the mechanism difference is significant:
| Property | GH secretagogues | IGF-1 LR3 |
|---|---|---|
| Pathway | Pituitary → GH → liver → IGF-1 | Direct IGF-1 receptor activation |
| Endogenous regulation | Intact — pituitary still controls GH release | Bypassed — direct receptor binding |
| GH levels | Elevated (pulsatile) | Unchanged or slightly suppressed (feedback) |
| IGF-1 elevation | Modest | Pronounced |
| Cycle length | 12–16 weeks typical | 4–6 weeks typical |
| Side-effect intensity | Mild | Moderate, sharper |
| Cost per cycle | $300–600 | $200–400 |
| Cancer-axis concern | Theoretical, modest | Theoretical, more pronounced |
The clean way to think about it: GH secretagogues produce a controlled, physiologic GH/IGF-1 increase that respects feedback regulation. IGF-1 LR3 produces a direct IGF-1 spike that bypasses regulation entirely. The latter is more potent and faster-acting; it's also more aggressive.
How IGF-1 LR3 is typically dosed
This is not education that fits the dose patterns of other peptides. IGF-1 LR3 is dosed in micrograms, much smaller than BPC-157 or GH secretagogues. The reported community protocols:
| Pattern | Daily total | Per-injection | Cadence |
|---|---|---|---|
| Conservative | 20 mcg | 20 mcg | Once daily, post-workout |
| Standard | 40 mcg | 20 mcg | Twice daily, pre + post-workout |
| Aggressive | 60–80 mcg | 30–40 mcg | Twice daily |
Above 80 mcg/day, side-effect intensity rises sharply and benefits don't reliably scale. Cycles run 4–6 weeks typically; longer than that and receptor downregulation plus the cancer-related caveats argue for a break.
For specific protocols, see IGF-1 LR3 dosing protocols.
Reconstitution math
IGF-1 LR3 ships in 1 mg vials almost universally (much smaller than other peptides because the dose is in micrograms). Standard mix:
1 mg vial + 1 mL bacteriostatic water = 1 mg/mL = 1000 mcg/mL.
A 20 mcg dose → 0.02 mL → 2 units on a U-100 insulin syringe.
A 40 mcg dose → 0.04 mL → 4 units.
The very small volumes are a real measurement challenge — 2 units on a 30-unit insulin syringe is hard to draw accurately. Some users dilute further (1 mg + 2 mL water = 4 units per 20 mcg) to make measurement easier. The reconstitution calculator handles either approach.
Stacking IGF-1 LR3
The most-reported stacks:
- IGF-1 LR3 + GH secretagogues — the secretagogue maintains GH-axis activity (which IGF-1 LR3 alone tends to suppress via feedback), while IGF-1 LR3 boosts the IGF-1 limb directly. Common pairing for body-comp goals.
- IGF-1 LR3 + BPC-157 — combines anabolic signaling with recovery support. Reported for hard training blocks where both adaptation and recovery matter.
- IGF-1 LR3 alone — defensible for short anabolic-focused cycles.
What not to stack:
- IGF-1 LR3 + synthetic HGH — doubling up on the GH/IGF-1 axis substantially compounds side-effect risk and is generally considered excessive
- IGF-1 LR3 + insulin — sometimes paired in advanced protocols, but the hypoglycemia risk is serious and this isn't a first-time-user combination
For more detail, see stacking IGF-1 LR3 with GH peptides.
Side effects and safety profile
IGF-1 LR3 has a more pronounced side-effect profile than GH secretagogues:
| Effect | Frequency | Severity |
|---|---|---|
| Hypoglycemia | Common, dose-dependent | Mild to moderate |
| Numbness or tingling in hands | Common | Mild |
| Carpal tunnel symptoms | Occasional | Moderate |
| Headaches | Occasional | Mild |
| Joint aches | Occasional | Mild |
| Fatigue | Common in first week | Mild |
| Increased appetite | Common | Variable |
The hypoglycemia risk is the most distinctive — IGF-1 LR3 has insulin-like effects and can lower blood glucose, particularly when injected pre-workout or on an empty stomach. Most users eat before injecting and avoid stacking with insulin.
Deeper coverage: IGF-1 LR3 side effects.
The cancer question — where IGF-1 LR3 differs
Every strength peptide carries some theoretical cancer concern via angiogenesis or growth-factor signaling. IGF-1 LR3 has the most concrete mechanism-based concern:
- IGF-1 is a documented growth factor for many cell types, including some cancer types
- Elevated IGF-1 levels have been associated with increased risk of certain cancers in epidemiological studies
- IGF-1 LR3 specifically produces sustained supraphysiologic IGF-1 receptor activation
- Pre-clinical data on IGF-1 LR3 specifically does not show direct tumor promotion in healthy tissue, but the receptor-activation mechanism is implicated in proliferation pathways
The right posture for IGF-1 LR3:
- Active or recent cancer: absolute contraindication
- Strong family history of hormone-sensitive cancer (breast, prostate, colorectal): discuss with a clinician before considering
- History of any malignancy: caution, even if remote
- No cancer history: the risk at standard doses for a 4–6 week cycle is theoretical, not measured — proceed informed
Legal and sourcing
IGF-1 LR3 is not FDA-approved for human use. It exists as a research chemical and is not on any compounding pathway. The sourcing reality is the same as other research-chem peptides — vendor quality varies, COAs matter, identity verification matters.
There is one specific sourcing concern: IGF-1 LR3 is sometimes counterfeited with cheaper peptides labeled as IGF-1 LR3. Mass spec verification on the COA is the only way to confirm identity. See vendor quality checks.
Who should and shouldn't use IGF-1 LR3
Most-fitting use cases:
- Experienced peptide users who have run GH secretagogues and want stronger anabolic signaling
- Specific body-comp goals where IGF-1 elevation is the lever
- Targeted training blocks (4–6 weeks) where you want maximum tissue-building support
Worst fit:
- First-time peptide users (the side-effect profile and risk picture are sharper than secretagogues)
- Anyone with active or recent cancer, or strong family history
- Pre-diabetics (the hypoglycemia risk and insulin-axis effects are real)
- Users not willing to set up baseline labs and end-of-cycle monitoring